NIH-funded research R01 grant

Better communication and medication support for people with lupus

Official title: CO-LEADER: Intervention to Improve Patient-Provider Communication and Medication Adherence among Patients with Systemic Lupus Erythematosus

Funded at Duke University · NIH-11310777 · Data updated 2026-11-12

This project trains clinicians and uses pharmacy refill records plus patient-reported barriers to help Black people with lupus take their medicines more reliably.

Quick facts

Grant typeR01 grant
Study typeNIH-funded research
Funding institutionDuke University
NIH-funded
Lab location1 site (Durham, United States)
Project startSeptember 23, 2023
Project endMarch 31, 2028
Funding year2026
Award (this year)$720,560
NIH project number5R01MD018977-04
Project IDNIH-11310777 on NIH RePORTER

Who could benefit from this research

Could help

Adults with systemic lupus erythematosus, especially Black patients who have missed refills or report difficulty taking prescribed lupus medications, are the ideal candidates.

Less likely to help

Patients without regular care at participating clinics, those not taking long-term lupus medications, or those whose challenges are unrelated to clinician communication may not benefit.

What this research studies

You would meet with clinicians who have been trained to communicate in ways that better address the concerns of Black patients with lupus. Clinicians will use pharmacy refill data together with what you tell them about barriers to taking medicines to guide conversations and create a plan. The program is designed to be simple and fit into regular clinic visits so it could be used widely if it works. Pilot data show the approach is feasible and the team will test whether it improves adherence and narrows racial gaps in lupus outcomes.

Why it matters

Potential benefit: If successful, this could increase trust, improve medication adherence, and help reduce racial disparities in lupus complications such as kidney failure.

How similar studies have gone: Previous adherence programs in SLE using reminders and education have had limited success, so this communication-focused use of refill data is relatively new though pilot results are promising.

Where this research is happening

  • Duke University
    Durham, United States
    Active

Researchers

  • Principal investigator: Sun, Kai — Duke University
  • Study coordinator: Sun, Kai

Related research

Other NIH-funded projects on the same topics.

  • Improving communication and medication adherence for Black patients with lupus

    This study is all about helping Black patients with lupus feel more comfortable talking to their doctors so they can stick to their medications better, by training healthcare providers in better communication and understanding the specific challenges these patients face.

    NIH research Duke University · Durham, United States · NIH-10934355

  • Immunostimulatory short non-coding RNAs and lupus

    A study in people with lupus looks at tiny RNA pieces that may spark inflammation, to understand if they drive disease activity.

    NIH research Thomas Jefferson University · Philadelphia, United States · NIH-11497703

  • Antiviral factors that limit HIV in people with SLE

    Researchers at Howard University are studying how immune factors in people with lupus may help limit HIV infection.

    NIH research Howard University · Washington, United States · NIH-11470887

  • Mechanistic clues about lupus from immune disorders

    This grant looks at why certain immune disorders in people with genetic immune problems lead to lupus-like symptoms, by studying patients and mouse models.

    NIH research Seattle Children's Hospital · Seattle, United States · NIH-11449228

  • Subjective thinking challenges in adults with lupus as they age

    This grant aims to understand how lupus-related cognitive problems affect adults, especially older adults, and tests a real-time method to track daily fluctuations in those symptoms.

    NIH research Hospital for Special Surgery · New York, UNITED STATES · NIH-11442899

  • Mitochondrial targets of antibodies in lupus (SLE)

    A Johns Hopkins-led study will identify which mitochondrial membrane proteins are targeted by autoantibodies in lupus patients to understand how these immune attacks fuel the disease.

    NIH research Johns Hopkins University · Baltimore, United States · NIH-11440181

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.